Fong L - Search Results

1

Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer.

Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L. Wei XX, et al. Among authors: fong l. Cancer Immunol Res. 2016 Nov;4(11):948-958. doi: 10.1158/2326-6066.CIR-16-0042. Epub 2016 Sep 29. Cancer Immunol Res. 2016. PMID: 27688020 Free PMC article.

2

Dendritic cells in cancer immunotherapy.

Fong L, Engleman EG. Fong L, et al. Annu Rev Immunol. 2000;18:245-73. doi: 10.1146/annurev.immunol.18.1.245. Annu Rev Immunol. 2000. PMID: 10837059 Review.

3

Immunotherapy for prostate cancer.

Fong L, Small EJ. Fong L, et al. Semin Oncol. 2003 Oct;30(5):649-58. doi: 10.1016/s0093-7754(03)00350-6. Semin Oncol. 2003. PMID: 14571412 Review.

4

Immunotherapy for prostate cancer.

Fong L, Small EJ. Fong L, et al. Curr Urol Rep. 2006 May;7(3):239-46. doi: 10.1007/s11934-006-0027-8. Curr Urol Rep. 2006. PMID: 16630528 Review.

5

A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G. Small EJ, et al. Among authors: fong l. Mol Ther. 2006 Jul;14(1):107-17. doi: 10.1016/j.ymthe.2006.02.011. Epub 2006 May 9. Mol Ther. 2006. PMID: 16690359 Free article. Clinical Trial.

6

Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor.

Rini BI, Fong L, Weinberg V, Kavanaugh B, Small EJ. Rini BI, et al. Among authors: fong l. J Urol. 2006 Jun;175(6):2087-91. doi: 10.1016/S0022-5347(06)00261-8. J Urol. 2006. PMID: 16697809

7

Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Rini BI, et al. Among authors: fong l. Cancer. 2006 Jul 1;107(1):67-74. doi: 10.1002/cncr.21956. Cancer. 2006. PMID: 16736512 Free article. Clinical Trial.

8

A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.

Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. Lin AM, et al. Among authors: fong l, fong k. BJU Int. 2006 Oct;98(4):763-9. doi: 10.1111/j.1464-410X.2006.06396.x. BJU Int. 2006. PMID: 16796694 Clinical Trial.

9

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.

Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. Small EJ, et al. Among authors: fong l. Clin Cancer Res. 2007 Mar 15;13(6):1810-5. doi: 10.1158/1078-0432.CCR-06-2318. Clin Cancer Res. 2007. PMID: 17363537 Clinical Trial.

10

Immunotherapy for prostate cancer.

Fong L, Small EJ. Fong L, et al. Curr Oncol Rep. 2007 May;9(3):226-33. doi: 10.1007/s11912-007-0026-z. Curr Oncol Rep. 2007. PMID: 17430695 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

681 results

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

681 results